Milestone Pharmaceuticals continues to face challenges as its CARDAMYST drug shows weak differentiation and poor market adoption against cheaper generics. In Q2, revenue was only $559K from over 1,200 prescriptions, hindered by heavy discounting and limited insurance coverage, with just 20% of the PSVT market covered. Financial health is worsening, with cash at $170M, a $39M burn in the first half, liabilities doubling to $163M, and equity dropping to $18M due to high expenses and growing royalty debts. Although expanding coverage and Medicare access might improve pricing, volume and adoption remain low, and future costs will pressure margins further.
Evotec reported a nearly 20% decline in revenue for the first half of 2026, alongside a sharp drop into negative adjusted EBITDA, signaling worsening fundamentals. Confidence in management's future targets has diminished, leading to a valuation based...
Shibarium has fixed its reported blockchain reorganization (reorg) issue as of September 19, 2026, resolving a key network disruption. However, the decentralized RPC (dRPC) migration and other infrastructure upgrades remain incomplete, with no set de...
Neutrl has opened redemptions for its NUSD stablecoin as the on-chain exchange rate approaches $0.51. This move allows holders to redeem their tokens, potentially stabilizing liquidity and market confidence. The redemption availability is significant...
US spot Bitcoin ETFs experienced significant inflows and outflows over five trading days, starting with $159.9 million inflows on Sept. 14, followed by $746.3 million in withdrawals over the next two days. However, demand returned strongly with $592....
X has filed a lawsuit in England against two named individuals and unidentified operators, accusing them of manipulating engagement across Bitcoin-focused accounts to fraudulently earn at least £207,384 through its Creator Revenue Sharing program. Th...
